Paige, the leader in computational pathology which is transforming the diagnosis and treatment of cancer, today announced it has received additional funding from Goldman Sachs Merchant Banking Division, which will be added to the recently announced Series B financing round. Paige will use this new capital to further develop the company’s diagnostic and test products for the biopharma industry, while strengthening its leadership position in clinical AI for pathologists and development of the Paige platform for remote viewing and routine clinical practice. Additionally, Paige has added David Castelblanco, Managing Director at Goldman Sachs, to its Board of Directors. David brings with him a wealth of experience as an investor and board member working with leading cancer treatment centers internationally.